Medincell SA (MEDCL) - Cash Flow Conversion Efficiency

Latest as of March 2026: -3.537x

Based on the latest financial reports, Medincell SA (MEDCL) has a cash flow conversion efficiency ratio of -3.537x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.84 Million ≈ $-12.67 Million USD) by net assets (€3.06 Million ≈ $3.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Medincell SA for the company's overall valuation and market capitalisation.

Medincell SA - Cash Flow Conversion Efficiency Trend (2016–2026)

This chart illustrates how Medincell SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Medincell SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medincell SA ranked by their cash flow conversion efficiency. Explore how high is Medincell SA's earnings quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Anteris Technologies Global Corp AU:AVR	-5.434x
Lincoln Educational Services NASDAQ:LINC	0.218x
Sirio Pharma SHE:300791	0.038x
Zhongzhong Science & Technology (Tianjin) Co. Ltd. A SHG:603135	N/A
Kyobo Securiti KO:030610	0.054x
ASRock Inc TW:3515	-0.040x
Shanghai Kaibao Pharmaceutical SHE:300039	0.045x
AP (Thailand) Public Company Limited BK:AP	0.039x

Annual Cash Flow Conversion Efficiency for Medincell SA (2016–2026)

The table below shows the annual cash flow conversion efficiency of Medincell SA from 2016 to 2026. View today's stock price for Medincell SA for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2026-03-31	€3.06 Million ≈ $3.58 Million	€-24.55 Million ≈ $-28.71 Million	-8.014x	-573.83%
2025-03-31	€-16.37 Million ≈ $-19.13 Million	€19.46 Million ≈ $22.76 Million	-1.189x	-507.24%
2024-03-31	€-40.82 Million ≈ $-47.73 Million	€-11.92 Million ≈ $-13.94 Million	0.292x	-41.20%
2023-03-31	€-42.29 Million ≈ $-49.45 Million	€-21.00 Million ≈ $-24.56 Million	0.497x	-68.91%
2022-03-31	€-13.37 Million ≈ $-15.63 Million	€-21.36 Million ≈ $-24.97 Million	1.598x	+217.37%
2021-03-31	€8.92 Million ≈ $10.42 Million	€-12.14 Million ≈ $-14.19 Million	-1.361x	-273.23%
2020-03-31	€-15.96 Million ≈ $-18.66 Million	€-12.54 Million ≈ $-14.66 Million	0.786x	+130.79%
2019-03-31	€6.24 Million ≈ $7.30 Million	€-15.93 Million ≈ $-18.63 Million	-2.552x	-652.58%
2018-03-31	€-11.75 Million ≈ $-13.74 Million	€-5.43 Million ≈ $-6.34 Million	0.462x	-68.86%
2017-03-31	€-2.29 Million ≈ $-2.67 Million	€-3.39 Million ≈ $-3.97 Million	1.483x	+2787.40%
2016-03-31	€1.32 Million ≈ $1.55 Million	€68.00K ≈ $79.50K	0.051x	--

About Medincell SA

PA:MEDCL France Biotechnology

Market Cap

$914.38 Million

€782.12 Million EUR

Market Cap Rank

#10025 Global

#155 in France

Share Price

€21.78

Change (1 day)

+0.09%

52-Week Range

€19.83 - €38.46

All Time High

€38.46